These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33238595)

  • 21. Worldwide legislative challenges related to psychoactive drugs.
    Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
    Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Psychoactive Substances: A Matter of Time.
    Pantano F; Graziano S; Pacifici R; Busardò FP; Pichini S
    Curr Neuropharmacol; 2019; 17(9):818-822. PubMed ID: 31577198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New and Emerging Illicit Psychoactive Substances.
    Graddy R; Buresh ME; Rastegar DA
    Med Clin North Am; 2018 Jul; 102(4):697-714. PubMed ID: 29933824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global strategy for New Psychoactive Substances: an update.
    Vicknasingam B; Narayanan S; Singh D; Corazza O
    Curr Opin Psychiatry; 2020 Jul; 33(4):295-300. PubMed ID: 32398543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A; Beck O; Hägerkvist R; Hultén P
    Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the 'added value' of European policy on new psychoactive substances.
    Chatwin C
    Int J Drug Policy; 2017 Feb; 40():111-116. PubMed ID: 27956185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New psychoactive substances of natural origin: A brief review.
    Feng LY; Battulga A; Han E; Chung H; Li JH
    J Food Drug Anal; 2017 Jul; 25(3):461-471. PubMed ID: 28911631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Air monitoring for illegal drugs including new psychoactive substances: A review of trends, techniques and thermal degradation products.
    Gent L; Paul R
    Drug Test Anal; 2021 Jun; 13(6):1078-1094. PubMed ID: 33870654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of toxicological and forensic analyses in the global challenge to health risks caused by new psychoactive substances.
    Zaami S; Busardò FP; Pichini S; Pacifici R; Marinelli E
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6008-6010. PubMed ID: 31364102
    [No Abstract]   [Full Text] [Related]  

  • 32. Emerging Agents of Substance Use/Misuse.
    Michienzi AE; Borek HA
    Emerg Med Clin North Am; 2022 May; 40(2):265-281. PubMed ID: 35461623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of new psychoactive substances in Northeast Asia from 2007 to 2015.
    Lee J; Yang S; Kang Y; Han E; Feng LY; Li JH; Chung H
    Forensic Sci Int; 2017 Mar; 272():1-9. PubMed ID: 28088088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.
    Pirona A; Bo A; Hedrich D; Ferri M; van Gelder N; Giraudon I; Montanari L; Simon R; Mounteney J
    Int J Drug Policy; 2017 Feb; 40():84-92. PubMed ID: 27956184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts].
    Bonnet U; Specka M; Soyka M; Alberti T; Bender S; Hilger J; Hillemacher T; Kuhlmann T; Kuhn J; Lüdecke C; Reimer J; Schneider U; Schroeder W; Stuppe M; Wiesbeck G; Wodarz N; Scherbaum N
    Fortschr Neurol Psychiatr; 2022 Jan; 90(1-02):19-29. PubMed ID: 33634461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMCDDA framework and practical guidance for naming synthetic cannabinoids.
    Pulver B; Fischmann S; Gallegos A; Christie R
    Drug Test Anal; 2023 Mar; 15(3):255-276. PubMed ID: 36346325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rise of new psychoactive substances and psychiatric implications: A wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies.
    Rinaldi R; Bersani G; Marinelli E; Zaami S
    Hum Psychopharmacol; 2020 May; 35(3):e2727. PubMed ID: 32144953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the UK Psychoactive Substances Act 2016 on episodes of toxicity related to new psychoactive substances as reported to the National Poisons Information Service. A time series analysis.
    Al-Banaa I; Hawkins L; Hill SL; Lupton DJ; Jackson G; Sandilands EA; Bradberry SM; Thompson JP; Rushton S; Thomas SHL
    Int J Drug Policy; 2020 Mar; 77():102672. PubMed ID: 32032867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Emergence of New Psychoactive Substance (NPS) Benzodiazepines. A Survey of their Prevalence in Opioid Substitution Patients using LC-MS.
    Mc Namara S; Stokes S; Nolan J
    Ir Med J; 2019 Aug; 112(7):970. PubMed ID: 31642644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.